Damon VidrineGina DeNicolaMatthew SchabathDamon Vidrine, Gina DeNicola, and Matthew Schabath were named research leaders at Moffitt.
Julie R. Park was named chair of the Department of Oncology at St. Jude Children’s Research Hospital.
The American Association for Cancer Research will award Carl H. June, fellow of the AACR Academy, with the 2023 AACR Award for Lifetime Achievement in Cancer Research during the AACR Annual Meeting 2023, April 14-19 in Orlando.
Vanessa B. Sheppard, associate director for community outreach and engagement and health disparities research at VCU Massey Cancer Center, received the American Cancer Society’s 2022 Researcher of the Year Award for her advances in cancer research.
After 10 months of planning and community engagement, the University of Chicago Medicine has updated its original proposal to build the city’s first freestanding cancer hospital with an enhanced design that incorporates feedback from patients and residents of the South Side.
Moffitt Cancer Center and IBA (Ion Beam Applications), are partnering to bring proton therapy treatment to Speros FL, Moffitt’s 775-acre Global Innovation Center located in Pasco County.
DKMS, the world’s largest blood stem cell donor center, received a $300,000 grant from the William G. Pomeroy Foundation to further its mission of providing patients battling blood cancer and blood diseases with lifesaving blood stem cell donors.
Takeda Oncology presented efficacy and safety data from the phase III PhALLCON trial studying Iclusig (ponatinib) in adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia during a virtual American Society of Clinical Oncology’s Plenary Series Program Feb. 15.
The updated National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Breast Cancer Version 1.2023 recognize Agendia Inc.’s MammaPrint UltraLow Risk result and its proven impact on patient care.
In a phase II, single-arm study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, patients with resectable non-small cell lung cancer who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes.
